Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
Metabolic syndrome is associated with increased inflammatory cytokines and reduced
adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned
that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin,
improving the inflammatory milieu associated with metabolic syndrome.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)